Treatment outcome among HIV-TB coinfected patients treated with single dose Dolutegravir 50mg and rifampicin-based therapy in a single centre in Bayelsa, Nigeria

Introduction: Current guidelines in the treatment of HIV/Tb coinfection recommends dolutegravir 50mg twice daily use in combination with rifampicin. In our unit we inadvertently omitted boosting the dolutegravir in coinfected patients on rifampicin-based therapy in both the intensive and continuous...

Full description

Saved in:
Bibliographic Details
Main Authors: Prof Tubonye Harry, Prof Dimie Ogoina, Dr Peter Nwakile, Prof Peter Ikuabe, Mr Jonathan Nanakede, Mr Samuel Ubong
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:International Journal of Infectious Diseases
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971224008233
Tags: Add Tag
No Tags, Be the first to tag this record!